Generic entry timeline

ELTROMBOPAG CHOLINE generics — when can they launch?

ELTROMBOPAG CHOLINE (ELTROMBOPAG CHOLINE) · · 4 active US patents · 0 expired

Earliest patent expiry
2038-11-05
12 years remaining
Full patent estate to
2038-11-05
complete protection through 2038
FDA approval
2023

Where ELTROMBOPAG CHOLINE sits in the generic timeline

Long-dated protection: earliest active US patent for ELTROMBOPAG CHOLINE extends to 2038 (~12 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 4 patents

FDA U-codes carved out by ELTROMBOPAG CHOLINE patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-3936(no description)
U-3937(no description)

Sample patent estate

Showing 4 of 4 active US patents. View full estate on the ELTROMBOPAG CHOLINE drug page →

  • US11072586 Method of Use · expires 2038-11-05
    This patent discloses solid state forms of eltrombopag choline, processes for preparing them, and pharmaceutical compositions.
    USPTO title: Solid state forms of eltrombopag choline
  • US11072586 Method of Use · expires 2038-11-05
    This patent discloses solid state forms of eltrombopag choline, processes for preparing them, and pharmaceutical compositions.
    USPTO title: Solid state forms of eltrombopag choline
  • US11072586 Method of Use · expires 2038-11-05
    This patent discloses solid state forms of eltrombopag choline, processes for preparing them, and pharmaceutical compositions.
    USPTO title: Solid state forms of eltrombopag choline
  • US11072586 Method of Use · expires 2038-11-05
    This patent discloses solid state forms of eltrombopag choline, processes for preparing them, and pharmaceutical compositions.
    USPTO title: Solid state forms of eltrombopag choline

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on ELTROMBOPAG CHOLINE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →